<DOC>
	<DOCNO>NCT00144079</DOCNO>
	<brief_summary>The trial examine clinical benefit adjuvant external beam radiotherapy ( RTx ) locally invasive differentiate carcinoma ( TNM stag pT4 pN0/1/x M0/x ; 5th ed . 1997 ) thyroid gland ( DTC ) . Patients treat surgery ( thyroidectomy lymphadenectomy ) , radioiodine therapy ( RIT ) ablate thyroid remnant tissue , TSH-suppressive L-thyroxine therapy without RTx document elimination cervical I-131 uptake .</brief_summary>
	<brief_title>Multicenter Study Differentiated Thyroid Carcinoma</brief_title>
	<detailed_description>MSDS design comprehensive cohort trial randomization observation arm . Patients enrol time first ablative radioiodine therapy ( RIT ) . Inclusion criterion papillary follicular DTC pT4 pN0/1/x M0/x , age 18 ( incl . ) 70 year ( excl . ) time initial surgery , completion primary surgical therapy R0 ( tumor residue ) R1 ( microscopic residue ) resection , Karnofsky index least 70 % , freedom distant metastasis time initial radioiodine therapy ( RIT ) , inform patient consent . Criteria exclusion secondary malignancy except basalioma , pregnancy , serious general disease , serious psychiatric disorder , inability give inform consent , previous RTx recurrence previous DTC . From 2003 , first inclusion criterion change DTC pT3/4 pN0/1/x M0/x reflect 2002 revision TNM staging system . The treatment protocol accordance current guideline Germany include total thyroidectomy ( TT ) central lymphadenectomy ( LNA ) , RIT ablate thyroid remnant , TSH-suppressive therapy L-thyroxine ( TSH &lt; 0.1 mU/l ) . RIT administer endogenous TSH-stimulation 4 week ’ cessation L-thyroxine use standard activity 1–4 , 1–2 , GBq I-131 patient 24-h-I-131 uptake 10 % 10–20 % , resp. , individual dosimetry aim least 300 Gy thyroid remnant . If scintigraphic I-131 uptake thyroid remnant persist whole-body scintigraphy ( least 200 MBq ; least 48 h ) 3 month RIT , second fraction RIT give 4–10 GBq . Patients consented randomization center actively take part randomization randomize treatment arm A ( additional adjuvant RTx ) B ( RTx ) 3 month initial RIT confirmation histological diagnosis reference pathologist distant metastasis exclude mean serum thyroglobulin ( Tg ) , WBS ( . . ) native thoracic compute tomogram ( CCT ) . Randomization stratify accord histological type ( papillary v. follicular ) , nodal status ( pN0/1/x ) , participate center , perform operator-independent randomization routine embed database . The remain patient assign arm A B participating center . RTx begin document elimination cervical I-131 uptake I-131 WBS 3 month last fraction ablative RIT . RT include thyroid bed ( unilateral tumor affect side ) dose 59.4 Gy 66.6 Gy R0 R1 resection , resp. , regional lymph node neck upper mediastinum include posterior cervical chain mandible mastoid process tracheal bifurcation dose 50.4 Gy 54.0 Gy pN0 pN1/x disease , resp . Fractionation conventional ( 1.8 Gy/d 5 day week ) . 3-D plan accord IRCU 50 mandatory . Patient follow-up include , minimum , out-patient appointment cervical ultrasound measurement serum TSH , hTG , anti-Tg antibody blood count 2 8 month RIT WBS , WBS ( least 200 MBq least 48 h ) endogenous TSH-stimulation 3 12 month ablative RIT 24-month interval . FDG-PET imaging modality perform need . At follow-up appointment , RTx toxicity record accord RTOG criterion quality life QLQ-C30 questionnaire ( v. 3.0 German ) EORTC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>papillary follicular thyroid carcinoma pT4 pN0/1/x M0/x completion primary surgical therapy R0 ( tumor residue ) R1 ( microscopic residue ) resection Karnofsky index &gt; 70 % freedom distant metastasis time initial radioiodine therapy inform patient consent secondary malignancy except basalioma pregnancy serious general disease serious psychiatric disorder inability give inform consent previous RTx recurrence previous thyroid cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Differentiated thyroid carcinoma</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>radioiodine therapy</keyword>
	<keyword>thyroidectomy</keyword>
</DOC>